Inclusion criteria were primary HIV-1 infection ( an incomplete HIV-1 western blot and detectable plasma HIV-RNA ) , with either symptoms or a CD4 + cell count below 500 cells per L. Patients were randomly assigned ( 1:1 ) to an intensive , five-drug cART regimen ( raltegravir 400 mg and maraviroc 150 mg twice daily , and a fixed-dose combination of tenofovir disoproxil fumarate 300 g plus emtricitabine 200 g , darunavir 800 g , and ritonavir 100 g once daily ) or a standard triple-drug cART regimen ( tenofovir disoproxil fumarate 300 g plus emtricitabine 200 g , darunavir 800 g , and ritonavir 100 g once daily ) using a predefined randomised list generated by randomly selected variable block sizes .